Benitec settles another lawsuit

By Melissa Trudinger
Tuesday, 24 August, 2004

RNAi company Benitec (ASX: BLT) has settled its second patent infringement lawsuit in two weeks, giving US company Genscript Corporation a non-exclusive worldwide licence to manufacture and sell DNA-directed RNAi (ddRNAi) products.

The lawsuit was one of three filed on March 22, 2004 against US companies Ambion, Genscript and Nucleonics. Ambion was granted a licence as part of a settlement announced on August 10. Financial details of the settlement and licence were not disclosed.

The company has also been granted a second UK patent related to its ddRNAi technology for use of ddRNAi expressed as hairpins in vertebrate animal cells, bringing the number of issued patents in the company's portfolio to eight.

Related News

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Cannabis use may double risk of cardiovascular disease death

Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd